STAR Strides Pharma Science Q2 FY26 results (Jul–Sep 2025) and concall
Strides Pharma delivered a strong Q2 FY26, marked by significant operating leverage and robust profitability growth. While the US market faced intense competition, the company maintained its focus on profitability over top-line growth. Other regulated markets showed strong double-digit growth, contributing to overall performance. The company also demonstrated financial discipline with debt reduction and improved capital efficiency.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 0.4%, net profit up 88.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 520 | 551 | 556 | 499 | 522 +0% |
| EBITDA | 55 | 74 | 68 | 67 | 62 +13% |
| Net profit | 17 | 15 | 16 | 13 | 32 +88% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
